| Robert C Owen, MD | |
|
6051 Highway 49, Hattiesburg, MS 39401-7200 | |
| (601) 288-7000 | |
| Not Available |
| Full Name | Robert C Owen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 6051 Highway 49, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073544615 | NPI | - | NPPES |
| 06782723 | Medicaid | MS | |
| P00270544 | Other | MS | RRGA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 18953 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Forrest General Hospital | Hattiesburg, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Relias Emergency Medicine Specialists Of Hattiesburg Llc | 9032549142 | 33 |
News Archive
UT Southwestern Medical Center psychiatry researchers have taken what they learned from their groundbreaking research on treating depression and are applying it to real-world clinical settings.
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").
Researchers from Ben-Gurion University, Israel, Harvard Medical School, Boston, and Tel Aviv University, Israel, have studied the correlation between large gatherings and hospitalization risk due to COVID-19. Their study titled, "Association of Mass Gatherings and COVID-19 Hospitalization," was published as a preprint on the medRxiv server.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Glioblastoma is the most aggressive brain tumor in adults. Now, it can be treated with neurosurgery, radiotherapy and chemotherapy. Still, the median life expectancy of patients affected with this pathology is no longer than 15 months.
› Verified 2 days ago
| Entity Name | Relias Emergency Medicine Specialists Of Hattiesburg Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609409440 PECOS PAC ID: 9032549142 Enrollment ID: O20200413002970 |
News Archive
UT Southwestern Medical Center psychiatry researchers have taken what they learned from their groundbreaking research on treating depression and are applying it to real-world clinical settings.
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").
Researchers from Ben-Gurion University, Israel, Harvard Medical School, Boston, and Tel Aviv University, Israel, have studied the correlation between large gatherings and hospitalization risk due to COVID-19. Their study titled, "Association of Mass Gatherings and COVID-19 Hospitalization," was published as a preprint on the medRxiv server.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Glioblastoma is the most aggressive brain tumor in adults. Now, it can be treated with neurosurgery, radiotherapy and chemotherapy. Still, the median life expectancy of patients affected with this pathology is no longer than 15 months.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert C Owen, MD Po Box 635614, Cincinnati, OH 45263-5614 Ph: () - | Robert C Owen, MD 6051 Highway 49, Hattiesburg, MS 39401-7200 Ph: (601) 288-7000 |
News Archive
UT Southwestern Medical Center psychiatry researchers have taken what they learned from their groundbreaking research on treating depression and are applying it to real-world clinical settings.
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").
Researchers from Ben-Gurion University, Israel, Harvard Medical School, Boston, and Tel Aviv University, Israel, have studied the correlation between large gatherings and hospitalization risk due to COVID-19. Their study titled, "Association of Mass Gatherings and COVID-19 Hospitalization," was published as a preprint on the medRxiv server.
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Glioblastoma is the most aggressive brain tumor in adults. Now, it can be treated with neurosurgery, radiotherapy and chemotherapy. Still, the median life expectancy of patients affected with this pathology is no longer than 15 months.
› Verified 2 days ago
Bradley Williams, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Miju Yu Kurtzweil, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Merit Health Wesley, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Dr. Carl Edward Johns Iii, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Trent Woods, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6051 Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Jacob Robert Fenster, Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Julie Marie Butler, ATC Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 118 College Dr, Hattiesburg, MS 39406 Phone: 601-268-5017 |